To evaluate whether off label nebulised vancomycin (Vancocin ® ) injection can be delivered via Pari LC Plus™ and e-flow rapid™ nebulisers. Objectives: To measure particle size, proportion of drug remaining in the nebuliser, degradation of product and percentage of drug delivered. Method: Vancomycin 250 mg (50 mg/ml-500 mg vial dissolved with 9.6 ml water for injection) were nebulised via both nebuliser systems. Particle size distributions were measured using a HELOS KF particle sizer (Sympatec, Germany) at 4 representative flow rates for children and adults. The proportion of drug remaining and percentage delivered were calculated by measuring residual volume and concentration. Sample degradation was evaluated by HPLC. Results: Pari LC Plus™ − median particle sizes ranged from 1.75-2.18 mm across the 4 flow rates; 61.6-73.9% of particles were between 1−5 mm in size. Of the nebulised dose, 81.2% was delivered with 18.8% remaining in the nebuliser. The residual concentration was 62.1 mg/ml compared to 50 mg/ml at initiation. There was no degradation after nebulisation. e-flow rapid™ − median particle sizes ranged from 3.33−3.6 mm across the 4 flow rates; 61.7−70% of particles were between 1−5 mm. Of the nebulised dose, 74% was delivered with 26% remaining in the nebuliser. The residual concentration was 48.8 mg/ml compared with 50 mg/ml initially. No degradation was seen. Conclusion: It is possible to nebulise vancomycin injection via both the Pari LC Plus™ and e-flow rapid™ nebulisers. The characteristics of the inhalation vary depending on the nebuliser used. It is not known if this is clinically significant.
P. Bruinenberg 1 , D. Serisier 2 , D. Cipolla 1 , J. Blanchard 1 . 1 Aradigm Corporation, Hayward, United States; 2 Mater Children's Hospital, Brisbane, Australia Ciprofloxacin (CP) for inhalation (CFI − [ARD-3100]) is an aqueous sustained release liposomal formulation for respiratory infections in cystic fibrosis (CF) and non-CF BE patients. Dual release CP for inhalation ) is a new inhaled formulation that matches the duration of release of CP from CFI, supporting 1× day administration, while providing higher initial concentration of CP in the lung to potentially provide enhanced concentration-dependent antimicrobial effect. Inhaled CFI in HV was safe and well tolerated resulting in plasma PK with an absorption-limited half life of 10.5 hr, compatible with 1× day administration. A reduction in P. aeruginosa sputum density (p < 0.01) and an increase in FEV 1 in CF patients were found. The current study evaluated the ability to modulate the PK of CFI to provide a higher Cmax while maintaining the duration of release. A single dose, cross-over trial comparing the safety, tolerability and plasma PK of two inhaled formulations (CFI vs. DRCFI) was conducted in 8 adult HV and DRCFI also in 6 BE subjects. Both formulations were safe and well tolerated in all subjects. In HV, the mean CP Cmax for CFI (169 ng/mL) was 2.5 times greater than for DRCFI (67 ng/mL) and the Tmax was faster for DRCFI (20 min vs. 1.8 hr). In BE and HV, the mean half-life of CFI was 9.7 and 9.4 hr, respectively, vs. 10.8 hr for CFI in HV. DRCFI matches the duration of release of CP from CFI, supporting 1 × day dosing, while providing a spike of CP in the lung to potentially enhance antimicrobial effects. High concentrations of CP was found in the sputum of BE subjects. Ongoing clinical trials evaluating CFI (ARD-3100) and DRCFI (ARD-3150) in CF are warranted. Main side effects for voriconazole is phototoxicity, sometimes leading to pemphigus-like skin lesions with blisters, also after short periods of sun exposure. Others are vomiting, vertigo, tachycardia, vision disturbances, photosensitivity, hallucinations, fever, shivering and nightmares. Side effects for posaconazole were gastric symptoms. Tiredness and nausea were side effects in both groups. Three patients who relapsed on voriconazole also relapsed on posaconazole.
114* Aspergillus fumigatus susceptibility to itraconazole in adult patients with cystic fibrosis
Conclusions: Treatment length is shorter, side effects and number of relapses are fewer with posaconazole. Time to relapse is shorter with posaconazole. The total cost per treatment is lower with posaconazole.
